Table 2.
Percentages of apoptotic ovarian cells following the absence or presence of paclitaxel
| DMSO | Paclitaxel (25nM) | Paclitaxel (1000 nM) | |
|---|---|---|---|
| TOV21G N | 6.00 | 58.60 | 63.00 |
| (±0.38) | (±4.50) | (±2.80) | |
| TOV21G R | 11.20 | 13.601 | 56.70 |
| (±5.50) | (±1.10) | (±30.70) | |
| TOV112D N | 1.80 | 63.20 | 82.00 |
| (±0.18) | (±0.50) | (±0.25) | |
| TOV112D R | 2.00 | 3.702 | 69.00 |
| (±0.27) | (±0.57) | (±0.87) | |
| COV504 N | 7.40 | 25.70 | 49.60 |
| (±4.40) | (±6.70) | (±25.30) | |
| COV504 R | 8.40 | 10.003 | 29.60 |
| (±4.40) | (±1.80) | (±6.20) |
Annexin V staining was used to determine the early detection of apoptotic cells and after 72 hours, apoptosis is evident in both native (N) and paclitaxel resistant (R) cell lines, in all three subtypes TOV21G, TOV112D and COV504. Both the native and resistant cell lines were exposed to increasing concentrations of paclitaxel; all three paclitaxel resistant cell lines exhibited reduced apoptotic induction when exposed to 25 and 1000 nM paclitaxel treatment (± standard deviation, average of 3 independent experiments). 1(p < 0.01) 2(p < 0.04) 3(p < 0.05) versus corresponding native groups